Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction is a research paper published in JACC Heart Failure (2024). On theSindex it has a DataRank of 0.567. It has been cited 16 times, with 12 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.425
From this paper's citation signal
Citation Network Contribution
0.142
From 11 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 12 citers.
NIA NIH HHS
Grant: R01 AG078153
NHLBI NIH HHS
Grant: U54 HL160273
NIDDK NIH HHS
Grant: P30 DK124723
NHLBI NIH HHS
Grant: R01 HL162828
NHLBI NIH HHS
Grant: U01 HL160272
NHLBI NIH HHS
Grant: R01 HL128526
NHLBI NIH HHS
Grant: R01 HL140731
NIA NIH HHS
Grant: U01 AG076928
NHLBI NIH HHS
Grant: K23 HL161348
NHLBI NIH HHS
Grant: U01 HL160226
NIA NIH HHS
Grant: U24 AG059624
NHLBI NIH HHS
Grant: R01 HL160689
NIA NIH HHS
Grant: P30 AG021332
NIA NIH HHS
Grant: R01 AG018915
NIA NIH HHS
Grant: R01 AG045551
NHLBI NIH HHS
Grant: R01 HL149423
AstraZeneca Pharmaceuticals LP
FWCI
5.03
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals